Alice Y Ho1, Shervin Tabrizi2,3, Samantha A Dunn2, Heather L McArthur4. 1. Department of Radiation Oncology, Cox Level 3, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA. alice.ho@mgh.harvard.edu. 2. Department of Radiation Oncology, Cox Level 3, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA. 3. Harvard Radiation Oncology Program, Boston, MA, USA. 4. Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Abstract
PURPOSE: Immune checkpoint inhibition (ICI) has demonstrated clinically significant efficacy when combined with chemotherapy in triple negative breast cancer (TNBC). Although many patients derived benefit, others do not respond to immunotherapy, therefore relying upon innovative combinations to enhance response. Local therapies such as radiation therapy (RT) and cryotherapy are immunogenic and potentially optimize responses to immunotherapy. Strategies combining these therapies and ICI are actively under investigation. This review will describe the rationale for combining ICI with targeted local therapies in breast cancer. METHODS: A literature search was performed to identify pre-clinical and clinical studies assessing ICI combined with RT or cryotherapy published as of August 2021 using PubMed and ClinicalTrials.gov. RESULTS: Published studies of ICI with RT and IPI have demonstrated safety and signals of early efficacy. CONCLUSION: RT and cryotherapy are local therapies that can be integrated safely with ICI and has shown promise in early trials. Randomized phase II studies testing both of these approaches, such as P-RAD (NCT04443348) and ipilimumab/nivolumab/cryoablation for TNBC (NCT03546686) are current enrolling. The results of these studies are paramount as they will provide long term data on the safety and efficacy of these regimens.
PURPOSE: Immune checkpoint inhibition (ICI) has demonstrated clinically significant efficacy when combined with chemotherapy in triple negative breast cancer (TNBC). Although many patients derived benefit, others do not respond to immunotherapy, therefore relying upon innovative combinations to enhance response. Local therapies such as radiation therapy (RT) and cryotherapy are immunogenic and potentially optimize responses to immunotherapy. Strategies combining these therapies and ICI are actively under investigation. This review will describe the rationale for combining ICI with targeted local therapies in breast cancer. METHODS: A literature search was performed to identify pre-clinical and clinical studies assessing ICI combined with RT or cryotherapy published as of August 2021 using PubMed and ClinicalTrials.gov. RESULTS: Published studies of ICI with RT and IPI have demonstrated safety and signals of early efficacy. CONCLUSION: RT and cryotherapy are local therapies that can be integrated safely with ICI and has shown promise in early trials. Randomized phase II studies testing both of these approaches, such as P-RAD (NCT04443348) and ipilimumab/nivolumab/cryoablation for TNBC (NCT03546686) are current enrolling. The results of these studies are paramount as they will provide long term data on the safety and efficacy of these regimens.
Authors: S Demaria; M D Volm; R L Shapiro; H T Yee; R Oratz; S C Formenti; F Muggia; W F Symmans Journal: Clin Cancer Res Date: 2001-10 Impact factor: 12.531
Authors: Evelyn L Kachikwu; Keisuke S Iwamoto; Yu-Pei Liao; John J DeMarco; Nzhde Agazaryan; James S Economou; William H McBride; Dörthe Schaue Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-17 Impact factor: 7.038
Authors: Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Rebecca Dent; Wedad M Hanna; Maureen Trudeau; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Breast Cancer Res Treat Date: 2008-06-10 Impact factor: 4.872
Authors: Peter Schmid; Hope S Rugo; Sylvia Adams; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Vidya Maiya; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: Lancet Oncol Date: 2019-11-27 Impact factor: 41.316
Authors: Aleix Prat; Cheng Fan; Aranzazu Fernández; Katherine A Hoadley; Rossella Martinello; Maria Vidal; Margarita Viladot; Estela Pineda; Ana Arance; Montserrat Muñoz; Laia Paré; Maggie C U Cheang; Barbara Adamo; Charles M Perou Journal: BMC Med Date: 2015-12-18 Impact factor: 8.775
Authors: Timothy R Wilson; Jianjun Yu; Xuyang Lu; Jill M Spoerke; Yuanyuan Xiao; Carol O'Brien; Heidi M Savage; Ling-Yuh Huw; Wei Zou; Hartmut Koeppen; William F Forrest; Jane Fridlyand; Ling Fu; Rachel Tam; Erica B Schleifman; Teiko Sumiyoshi; Luciana Molinero; Garret M Hampton; Joyce A O'Shaughnessy; Mark R Lackner Journal: NPJ Breast Cancer Date: 2016-07-13